ESC Premium Access

Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study

Congress Presentation

About the speaker

Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)
27 presentations

6 more presentations in this session

A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular disease

Speaker: Professor T. Chao (Tainan, TW)


Effect of de-escalated switching dual antiplatelet therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: real-world data from a nationwide cohort study

Speaker: Doctor C. Hsu (Taipei, TW)


Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study

Speaker: Doctor J. Russo (Ottawa, CA)


Comparing treatment recommendations for the DAPT and PRECISE-DAPT scores after percutaneous coronary intervention

Speaker: Doctor R. Boudreau (Ottawa, CA)


Platelet inhibitory profiles of prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes undergoing percutaneous coronary intervention: results of a randomized feasibility study

Speaker: Professor D. Angiolillo (Jacksonville, US)


Access the full session

Evolving developments in anti-platelet therapy

Speakers: Professor D. Angiolillo, Professor T. Chao, Doctor C. Hsu, Doctor J. Russo, Doctor R. Boudreau...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb